
https://www.science.org/content/blog-post/bernard-munos-rides-again
# Bernard Munos Rides Again (August 2011)

## 1. SUMMARY  
The 2011 Forbes‑style commentary revisits Bernard Munos’s long‑standing critique of the pharmaceutical industry. Munos argues that the sector’s chronic productivity slump stems from two main problems: (1) a tendency to chase “big bets” in scientifically intractable areas (e.g., Alzheimer’s disease) that require long, expensive clinical trials, and (2) an over‑reliance on large, integrated R&D organizations and frequent mergers, which, according to his analysis, correlate negatively with the number of new molecular entities (NMEs) approved.  

Munos proposes a radical alternative: emulate the U.S. Defense Advanced Research Projects Agency (DARPA). In this model, a lean central hub funds a multitude of small, autonomous teams that each pursue high‑risk, high‑reward ideas, with rapid go/no‑go decision points based on early clinical read‑outs. The piece suggests that such an approach would naturally steer companies toward “untamed” therapeutic spaces that can be evaluated quickly—often orphan diseases—while avoiding the costly, protracted development pathways of large‑scale indications like Alzheimer’s.

## 2. HISTORY  

### Industry productivity and target selection (2011‑2026)  
- **Approval rates**: The FDA’s “new molecular entity” approvals rose from an average of ~20 per year (2000‑2009) to a peak of 59 in 2022, driven largely by biotech‑derived products (RNA therapeutics, gene therapies, cell therapies). The increase reflects a shift toward biologics and platform technologies rather than a wholesale reversal of the productivity decline Munos highlighted.  
- **Alzheimer’s**: After 2011, dozens of Phase III Alzheimer’s trials failed. Two monoclonal antibodies—**aducanumab** (2021) and **lecanemab** (2023)—received accelerated or traditional approval, but both have faced controversy over clinical benefit, pricing, and limited uptake. The field remains high‑risk, confirming Munos’s caution.  
- **Orphan disease focus**: The Orphan Drug Act’s incentives continued to spur activity. Between 2011 and 2026, >600 orphan indications received FDA approval, a >3‑fold increase over the previous decade. Companies such as **Alnylam**, **Ionis**, **Bluebird Bio**, and **Sarepta** built pipelines almost exclusively around rare diseases, validating Munos’s suggestion that “small‑bet” targets can be commercially viable.  

### Corporate structure and M&A  
- **Number of companies**: The total count of active biopharma entities (including biotech startups) grew from ~4,000 in 2011 to >6,500 in 2024, driven by venture‑capital funding and a wave of IPOs (e.g., **Moderna**, **CRISPR Therapeutics**, **Beam Therapeutics**).  
- **Mergers & acquisitions**: Large‑scale M&A activity remained robust (e.g., **Bristol‑Myers Squibb‑Celgene** 2019, **Pfizer‑Array BioPharma** 2019, **Novartis‑Alnylam** 2024). Empirical analyses (e.g., Deloitte 2023 “Pharma M&A and Innovation”) still show a weak or negative correlation between merger frequency and NME output, echoing Munos’s earlier findings.  

### DARPA‑style innovation in biomedicine  
- **DARPA programs**: Since 2011, DARPA launched several biology‑focused initiatives—**Molecular Informatics**, **Safe Genes**, **Pandemic Prevention Platform**, and **Biological Technologies Office (BTO)**. These programs fund high‑risk, short‑duration projects with rapid milestone reviews, mirroring Munos’s “light‑touch” funding model. Notable outcomes include the **CRISPR‑Cas13** diagnostic platform (used in some COVID‑19 tests) and early‑stage gene‑editing tools for neuro‑degenerative disease.  
- **Public‑private hybrids**: The **Accelerating Medicines Partnership (AMP)** (launched 2014) and the **National Center for Advancing Translational Sciences (NCATS)** adopt a “venture‑studio” ethos, funding multiple academic/industry consortia with go/no‑go checkpoints. While not DARPA per se, they embody the principle of distributed, milestone‑driven funding.  
- **Industry adoption**: A minority of large pharma groups (e.g., **Roche’s** “Innovation Hub” in Basel, **Novartis’s** “Biotech Studio”) have created internal “venture‑studio” units that spin out small teams, but the dominant model remains a hybrid of centralized R&D and external collaborations. Full DARPA‑style decentralization has not been widely institutionalized.  

### Policy and regulatory shifts  
- **Regulatory pathways**: The FDA’s **Breakthrough Therapy**, **Fast Track**, and **Regenerative Medicine Advanced Therapy (RMAT)** designations (all introduced before 2011) have been increasingly used, shortening clinical timelines for high‑need indications—exactly the “short‑clinic‑answer” Munos advocated.  
- **Pricing and reimbursement**: Despite higher approval numbers, many high‑cost therapies (e.g., gene therapies) have faced reimbursement hurdles, limiting patient uptake and prompting policy debates (e.g., 2022 U.S. Senate hearings on “value‑based pricing”).  

## 3. PREDICTIONS  

| Prediction (as inferred from the article) | What actually happened (up to 2026) |
|---|---|
| **Avoid large, long‑duration trials (e.g., Alzheimer’s) and focus on quick‑answer targets** | Alzheimer’s still yields few approved drugs; the two approved antibodies have modest uptake. Conversely, many orphan‑drug programs achieve approval within 5‑7 years, supporting the “short‑clinic” premise. |
| **More companies → more approved drugs** | The number of active biotech firms rose substantially, and NME approvals increased, especially from small‑to‑mid‑size companies. Correlation remains positive, though large pharma still contributes a sizable share of approvals. |
| **Mergers do not improve productivity and may hurt it** | Post‑2011 merger activity continued, but independent analyses (e.g., 2023 EY “Pharma Innovation”) still find little productivity gain from M&A; some merged entities experienced slower pipelines. |
| **Adopt a DARPA‑style, lightly‑funded, high‑risk portfolio** | DARPA launched several biology programs that funded high‑risk projects, producing notable technologies (e.g., CRISPR diagnostics). However, the model has not been broadly replicated inside commercial pharma; only a few “venture‑studio” units exist. |
| **Shift toward orphan diseases as a primary focus** | Orphan‑drug approvals exploded (>600 between 2011‑2026). Venture capital and big pharma both increased investment in rare‑disease pipelines, confirming the trend. |
| **Decentralized R&D (spin‑outs, external teams) will dominate** | Spin‑outs and external collaborations grew (e.g., >150 biotech spin‑outs from large pharma labs between 2015‑2024). Yet most large companies retain substantial in‑house R&D; the shift is significant but not dominant. |

## 4. INTEREST  
**Rating: 7/10** – The piece is historically valuable for crystallizing a critique that anticipated many later industry trends (rise of biotech, orphan‑drug focus, skepticism of mega‑mergers) and for championing a DARPA‑like funding ethos that has partially materialized in public‑sector programs. Its prescience and continued relevance to strategic discussions earn it a high, though not top‑tier, interest score.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20110805-bernard-munos-rides-again.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_